Commissioner Scott Gottlieb published a statement that FDA is taking actions to ensure “compounding remains a practice of customizing medications for individual patients whose needs cannot be met by FDA-approved drugs.”
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
